Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptus PharmaBOM:544529 +3.63%18 ROA % is 13.83% as of Mar. 2026, which is 15% above its 10-year median of 11.98. GuruFocus rates BOM:544529 with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 120 Medical Distribution companies, Aptus Pharma ranks better than 95.83% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Aptus Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹57.5 Mil.
Aptus Pharma's average Total Assets over the quarter that ended in Mar. 2026 was ₹415.6 Mil. Therefore, Aptus Pharma's annualized ROA % for the quarter that ended in Mar. 2026 was 13.83%.
The historical rank and industry rank for Aptus Pharma's ROA % or its related term are showing as below:
BOM:544529'
s ROA % Range Over the Past 10 Years
Min: 3.13 Med: 11.98 Max: 19.4
Current: 13.19
During the past 4 years, Aptus Pharma's highest ROA % was 19.40%. The lowest was 3.13%. And the median was 11.98%.
BOM:544529's ROA % is ranked better than 95.83% of 120
companies
in the Medical Distribution industry
Industry Median: 2.215
vs BOM:544529: 13.19
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Aptus Pharma ROA % Related Terms
Aptus Pharma ROA % Historical Data
* Premium members only.
The historical data trend for Aptus Pharma's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Aptus Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptus Pharma ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Aptus Pharma's ROA % distribution charts can be found below:
* The bar in red indicates where Aptus Pharma's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Aptus Pharma (BOM:544529) has a ROA % of 13.83% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Aptus Pharma and its competitors. This is 15% above median its historical median of 11.98. Over the past decade, Aptus Pharma's ROA % has ranged from 3.13 to 19.40. According to the industry distribution chart, Aptus Pharma ranks #5 out of 120 companies in the Medical Distribution industry, placing it in the top 4.2%.
Is Aptus Pharma's ROA % too high?
Aptus Pharma's current ROA % of 13.83% is 15% above median its 10-year median of 11.98. Over the past 10 years, this metric has ranged from a low of 3.13 to a high of 19.40. The Medical Distribution industry median ROA % is 2.22. Aptus Pharma's value of 13.83% is 524.4% above this industry median. Based on the distribution chart, Aptus Pharma ranks #5 out of 120 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Aptus Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Aptus Pharma's ROA % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Aptus Pharma ranks #5 out of 120 companies for ROA %. This places Aptus Pharma in the top 4% of its industry — outperforming the majority of peers. The industry median ROA % is 2.22. Aptus Pharma's value of 13.83% is 524.4% above this benchmark. Historically, Aptus Pharma's own ROA % has ranged from 3.13 to 19.40 over the past decade. While the company's 10-year median is 11.98 vs. the industry median of 2.22, Aptus Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.22, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptus Pharma's current ROA % of 13.83% is 524.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Aptus Pharma and its competitors. For the Medical Distribution industry, the median ROA % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptus Pharma's current ROA % is 13.83%, which is 15% above median its own 10-year median of 11.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptus Pharma stock overvalued right now?
Aptus Pharma (BOM:544529) has a current ROA % of 13.83%. The current ROA % is 13.83%, which is 15% above median its 10-year median of 11.98 and 524.4% above the Medical Distribution industry median of 2.22. Aptus Pharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Aptus Pharma (BOM:544529), the current ROA % is 13.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. The group provides a diverse range of pharmaceutical products catering to various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
18GF Score
Get the complete analysis for BOM:544529
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544529 has been successfully added to your 
